Which factor can lead to gaps in current drug therapy outcomes?

Which factor can lead to gaps in current drug therapy outcomes?

• A. Outcomes never change after initial trials.
• B. Outcomes are derived from animal studies only.
• C. Outcomes are derived from clinical trials, which are altered if post-marketing surveillance data indicate a need.
• D. Outcomes are fixed once a drug is approved.

Answer: (C)

The key idea is that drug therapy outcomes are not fixed after approval; they evolve as real-world data become available. After a medicine is on the market, pharmacovigilance collects reports on safety, effectiveness, and how it works in diverse patients outside the controlled trial setting. This post-marketing information can reveal issues related to tolerability, rare adverse events, interactions with other drugs, or use in populations not well represented in trials. When such data indicate a need, regulatory bodies may update labeling, dosing recommendations, approved indications, or safety warnings. Those updates can change how well the therapy performs in practice, creating gaps between what was predicted in trials and what is seen in everyday use. Why the other ideas don’t fit: outcomes don’t stay static after trials; they can change as new evidence emerges. Relying only on animal studies won’t capture human responses and won’t address real-world effectiveness. And once approved, outcomes aren’t fixed—the regulatory framework allows ongoing updates to reflect new information.

The key idea is that drug therapy outcomes are not fixed after approval; they evolve as real-world data become available. After a medicine is on the market, pharmacovigilance collects reports on safety, effectiveness, and how it works in diverse patients outside the controlled trial setting. This post-marketing information can reveal issues related to tolerability, rare adverse events, interactions with other drugs, or use in populations not well represented in trials. When such data indicate a need, regulatory bodies may update labeling, dosing recommendations, approved indications, or safety warnings. Those updates can change how well the therapy performs in practice, creating gaps between what was predicted in trials and what is seen in everyday use.

Why the other ideas don’t fit: outcomes don’t stay static after trials; they can change as new evidence emerges. Relying only on animal studies won’t capture human responses and won’t address real-world effectiveness. And once approved, outcomes aren’t fixed—the regulatory framework allows ongoing updates to reflect new information.